Durect Newsroom

Oppenheimer Maintains Durect(DRRX.US) With Buy Rating, Maintains Target Price $5

Futu NewsNov 26 21:31

Oppenheimer Remains a Buy on Durect (DRRX)

TipRanksNov 26 20:49

Northland Securities Maintains Durect(DRRX.US) With Buy Rating, Maintains Target Price $8.5

Futu NewsNov 25 23:33

Northland Securities Maintains Durect(DRRX.US) With Buy Rating, Maintains Target Price $8.5

Futu NewsNov 14 22:31

Northland Securities Sticks to Its Buy Rating for Durect (DRRX)

TipRanksNov 14 21:59

Oppenheimer Maintains Durect(DRRX.US) With Buy Rating, Maintains Target Price $5

Futu NewsNov 14 21:31

H.C. Wainwright Maintains Durect(DRRX.US) With Hold Rating

Futu NewsNov 14 19:33

H.C. Wainwright Remains a Hold on Durect (DRRX)

TipRanksNov 14 19:31

Durect Analyst Ratings

BenzingaNov 14 19:22

Durect Analyst Ratings

BenzingaSep 26 18:40

H.C. Wainwright Maintains Durect(DRRX.US) With Hold Rating

Futu NewsSep 26 18:31

Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)

TipRanksAug 14 18:43

H.C. Wainwright Maintains Durect(DRRX.US) With Hold Rating

Futu NewsAug 14 18:34

Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)

TipRanksMay 22 21:10

Durect Analyst Ratings

BenzingaMay 22 18:30

Durect Analyst Ratings

BenzingaMay 15 22:55

Durect (DRRX) Gets a Buy From Oppenheimer

TipRanksMay 14 20:02

Durect Analyst Ratings

BenzingaApr 1 21:20

Oppenheimer Reiterates Outperform on Durect, Maintains $5 Price Target

BenzingaApr 1 21:20

Durect Analyst Ratings

BenzingaMar 28 20:10